Stock Research for ATOS

ATOS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ATOS Stock Chart & Research Data

The ATOS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATOS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ATOS Due diligence Resources & Stock Charts

The ATOS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ATOS Detailed Price Forecast - CNN Money CNN View ATOS Detailed Summary - Google Finance
Yahoo View ATOS Detailed Summary - Yahoo! Finance Zacks View ATOS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ATOS Trends & Analysis - Trade-Ideas Barrons View ATOS Major Holders - Barrons
NASDAQ View ATOS Call Transcripts - NASDAQ Seeking View ATOS Breaking News & Analysis - Seeking Alpha
Spotlight View ATOS Annual Report - CompanySpotlight.com OTC Report View ATOS OTC Short Report - OTCShortReport.com
TradeKing View ATOS Fundamentals - TradeKing Charts View ATOS SEC Filings - Bar Chart
WSJ View Historical Prices for ATOS - The WSJ Morningstar View Performance/Total Return for ATOS - Morningstar
MarketWatch View the Analyst Estimates for ATOS - MarketWatch CNBC View the Earnings History for ATOS - CNBC
StockMarketWatch View the ATOS Earnings - StockMarketWatch MacroAxis View ATOS Buy or Sell Recommendations - MacroAxis
Bullish View the ATOS Bullish Patterns - American Bulls Short Pains View ATOS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ATOS Stock Mentions - StockTwits PennyStocks View ATOS Stock Mentions - PennyStockTweets
Twitter View ATOS Stock Mentions - Twitter Invest Hub View ATOS Investment Forum News - Investor Hub
Yahoo View ATOS Stock Mentions - Yahoo! Message Board Seeking Alpha View ATOS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ATOS - SECform4.com Insider Cow View Insider Transactions for ATOS - Insider Cow
CNBC View ATOS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ATOS - OTC Markets
Yahoo View Insider Transactions for ATOS - Yahoo! Finance NASDAQ View Institutional Holdings for ATOS - NASDAQ


Stock Charts

FinViz View ATOS Stock Insight & Charts - FinViz.com StockCharts View ATOS Investment Charts - StockCharts.com
BarChart View ATOS Stock Overview & Charts - BarChart Trading View View ATOS User Generated Charts - Trading View




Latest Financial News for ATOS


Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program
Posted on Wednesday July 18, 2018

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC (“TD2”). “While there has been recent success treating blood cancers with chimeric antigen receptor therapy (or, CAR-T), there has not been much success using CAR-T to treat solid tumors like breast cancer,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa.


Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer
Posted on Friday July 13, 2018

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened a Phase 2 study of its proprietary oral Endoxifen to treat breast cancer in the “window of opportunity” setting, which is the period between diagnosis of breast cancer and surgery. “Once a patient is diagnosed with breast cancer, there is a window of time, typically a number of weeks, before definitive surgery is performed,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa. “Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in estrogen-receptor-positive patients during this ‘window of opportunity.' Tamoxifen, the current standard of care, has not been effective in this setting, probably because it can take 50-200 days to reach steady-state of Endoxifen blood levels, while the surgery is usually completed within 30 to 45 days of diagnosis.


''Strong Economy, Trade Wars & Market Volatility''
Posted on Wednesday June 27, 2018

SAN FRANCISCO, CA / ACCESSWIRE / June 27, 2018 / Vista Partners ("Vista") has published June's FREE Macroeconomic & Investment Monthly Newsletter, "Strong Economy, Trade Wars & Market Volatility." ...


Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density
Posted on Tuesday June 26, 2018

Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened its Phase 2 study of proprietary topical Endoxifen on mammographic breast density, or MBD, reduction. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer and may potentially improve the accuracy of mammography in finding cancer.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.